0.790
0.02 (2.60%)
| 前收盘价格 | 0.770 |
| 收盘价格 | 0.770 |
| 成交量 | 126,946 |
| 平均成交量 (3个月) | 315,546 |
| 市值 | 103,492,376 |
| 价格/销量 (P/S) | 103.68 |
| 股市价格/股市净资产 (P/B) | 10.23 |
| 52周波幅 | |
| 利润日期 | 23 Aug 2024 |
| 营业毛利率 | -194.62% |
| 营业利益率 (TTM) | -105.55% |
| 稀释每股收益 (EPS TTM) | -0.050 |
| 季度收入增长率 (YOY) | 10.10% |
| 总债务/股东权益 (D/E MRQ) | 3.42% |
| 流动比率 (MRQ) | 10.13 |
| 营业现金流 (OCF TTM) | -5.59 M |
| 杠杆自由现金流 (LFCF TTM) | -3.61 M |
| 资产报酬率 (ROA TTM) | -40.22% |
| 股东权益报酬率 (ROE TTM) | -73.77% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (AU) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | PROTEOMICS FPO [PIQ] | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.75 |
|
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 29.17% |
| 机构持股比例 | 7.08% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合